Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Booster Dose of dTpa and pa Vaccines vs Td Vaccine in Healthy Adults
NCT01262924Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 1997
- Primary completion
- Dec 1998
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, single-blind trial of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) and acellular pertussis vaccine in diphtheria, Tetanus and pertussis (3 arms), sponsored by GSK. Primary endpoint: Immunogenicity with respect to components of the study vaccines at 1 month. Started Oct 1997; status: completed.
02
Drugs
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)acellular pertussis vaccine
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on NCT01262924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01262924.